ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
November 05, 2024 07:00 ET | ZyVersa Therapeutics
Inflammasome-driven inflammation in obesity results in severely damaged pancreatic islets, leading to islet cell loss and metabolic dysfunction.
GMILogo_Vertical-Gradient.png
Prediabetes Market to hit USD 360.6 million by 2032, says Global Market Insights Inc.
November 05, 2024 06:00 ET | Global Market Insights Inc.
Selbyville, Delaware, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Prediabetes Market size is estimated to reach USD 360.6 million by the end of 2032. The industry growth is driven by the increasing global...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes
January 31, 2024 07:57 ET | ZyVersa Therapeutics
NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications (e.g., Type 2 Diabetes, Hypertension, Heart Disease).
Research Nester Logo.jpg
Cardiometabolic Drugs Market revenue to exceed USD 72 Billion by 2035, says Research Nester
August 21, 2023 06:00 ET | Research Nester
New York, Aug. 21, 2023 (GLOBE NEWSWIRE) -- The global Cardiometabolic Drugs Market size is projected to expand at ~ 6% CAGR between 2023 and 2035. The market is expected to garner a revenue of USD...
new_logo.png
GLP-1 Receptor Agonist Market to reach USD 55.8 billion by 2032, Says Graphical Research Powered by GMI
June 13, 2023 17:30 ET | Graphical Research
Selbyville, Delaware, June 13, 2023 (GLOBE NEWSWIRE) -- GLP-1 Receptor Agonist Market size is estimated to amass USD 55.8 billion by 2032. The industry is set to observe notable growth driven...